{
    "EU-1-21-1541_h_dec_0.pdf": {
        "file_link": "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/dec_154987_en.pdf",
        "file_date": "2022-03-24 00:00:00",
        "medicine_updated": "2022-11-27 13:48:10.267640"
    },
    "EU-1-21-1541_h_anx_0.pdf": {
        "file_link": "https://ec.europa.eu/health/documents/community-register/2022/20220324154987/anx_154987_en.pdf",
        "file_date": "2022-03-24 00:00:00",
        "medicine_updated": "2022-11-27 13:48:10.394626"
    },
    "EU-1-21-1541_h_public-assessment-report.pdf": {
        "file_link": "https://www.ema.europa.eu/documents/assessment-report/dasatinib-accordpharma-epar-public-assessment-report_en.pdf",
        "file_date": "2022-11-26 14:41:42.747639",
        "medicine_updated": "2022-11-26 14:41:42.747639"
    },
    "EU-1-21-1541_h_epar_other_0.pdf": {
        "file_link": "https://www.ema.europa.eu/documents/procedural-steps-after/dasatinib-accordpharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf",
        "file_date": "2022-11-26 11:55:04.214949",
        "medicine_updated": "2022-11-26 11:55:04.214949"
    },
    "EU-1-21-1541_h_epar-other_0.pdf": {
        "file_link": "https://www.ema.europa.eu/documents/procedural-steps-after/dasatinib-accordpharma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf",
        "file_date": "2022-11-26 14:41:42.748633",
        "medicine_updated": "2022-11-26 14:41:42.748633"
    }
}